Figure 4. HSV-2 infection of moDCs induces α₄β₇ on CD4⁺ T cells.

Mock-, UV-HSV-2-, or Live HSV-2-treated DCs (Figure 3) were mixed with autologous CD4⁺ T cells and cultured for 5 days. A) The gating strategy for the definition of the α₄β₇ ^high (HIGH) (memory cells), α₄β₇ ^int (INT) (memory cells) and α₄β₇ ^low (LOW) (naïve cells) and CD69⁺ subsets is shown for 1 representative of 11 independent experiments. B–C) The fold changes (mean ± SEM, 11 independent experiments) in the percentage of α₄β₇ ^highCD3⁺CD4⁺ T cells (B) and CD69⁺CD3⁺CD4⁺ T cells (C) in the absence (−) or presence (+) of an RARα antagonist are shown relative to the mock-treated controls (set as 1). A T cell only control (no DCs, T ONLY), not exposed to HSV-2, was included alongside. (*p<0.05, **<0.01, ***p≤0.001).